Giotta Francesco, Acito Luigi, Candeloro Giampiero, Del Medico Pietro, Gadaleta-Caldarola Gennaro, Giordano Guido, Gueli Rossana, Lugini Antonio, Magri Valentina, Mandarà Marta, Masci Giovanna, Pisconti Salvatore, Pistelli Mirco, Rizzi Anna, Salesi Nello, Schirone Alessio, Scognamiglio Giovanni, Tedeschi Maria, Zucchinelli Patrizia
Oncologia Medica, Istituti di Ricovero e Cura a Carattere Scientifico, Istituto Tumori "Giovanni Paolo II," Bari, Italy
Oncologia Medica, Ospedale A. Murri, Fermo, Italy.
Oncologist. 2016 Nov;21(11):1298-1305. doi: 10.1634/theoncologist.2016-0022. Epub 2016 Oct 14.
Evidence on the management and treatment of male breast cancer is scant. We report the analysis of a multicenter Italian series of patients with male breast cancer treated with eribulin. To our knowledge, this is the first report on the use or eribulin in this setting.
Patients were retrospectively identified in 19 reference centers. All patients received eribulin treatment, according to the standard practice of each center. Data on the identified patients were collected using a standardized form and were then centrally reviewed by two experienced oncologists.
A total of 23 patients (median age, 64 years; range, 42-80) were considered. The median age at the time of diagnosis of breast cancer was 57 years (range, 42-74). HER2 status was negative in 14 patients (61%), and 2 patients (9%) had triple-negative disease. The most common metastatic sites were the lung ( = 14; 61%) and bone ( = 13; 56%). Eribulin was administered for a median of 6 cycles (range, 3-15). All patients reported at least stable disease; two complete responses (9%) were documented. Eribulin was well-tolerated, with only four patients (17%) reporting grade 3 adverse events and two (9%) with treatment interruptions because of toxicity. Eight subjects (35%) did not report any adverse event during treatment. For patients with a reported fatal event, the median overall survival from the diagnosis of metastatic disease was 65 months (range, 22-228).
Although hampered by all the limitations of any retrospective case series, the results of the present study suggest, for the first time, the use of eribulin as therapy for male breast cancer.
Evidence on the management and treatment of male breast cancer is eagerly awaited. Although hampered by all the limitations of any retrospective case series, the results of the present study suggest, for the first time, the use of eribulin as therapy for male breast cancer.
关于男性乳腺癌管理与治疗的证据匮乏。我们报告了对意大利多中心一组接受艾日布林治疗的男性乳腺癌患者的分析。据我们所知，这是关于艾日布林在该情况下应用的首份报告。
在19个参考中心对患者进行回顾性识别。所有患者均按照各中心的标准做法接受艾日布林治疗。使用标准化表格收集所识别患者的数据，然后由两名经验丰富的肿瘤学家进行集中审查。
共纳入23例患者（中位年龄64岁；范围42 - 80岁）。乳腺癌诊断时的中位年龄为57岁（范围42 - 74岁）。14例患者（61%）HER2状态为阴性，2例患者（9%）为三阴性疾病。最常见的转移部位是肺（n = 14；61%）和骨（n = 13；56%）。艾日布林的中位给药周期数为6个周期（范围3 - 15个周期）。所有患者均报告至少病情稳定；记录到2例完全缓解（9%）。艾日布林耐受性良好，仅有4例患者（17%）报告3级不良事件，2例（9%）因毒性而中断治疗。8名受试者（35%）在治疗期间未报告任何不良事件。对于报告有致命事件的患者，从转移性疾病诊断起的中位总生存期为65个月（范围22 - 228个月）。
尽管受到任何回顾性病例系列的所有局限性的影响，但本研究结果首次表明艾日布林可用于男性乳腺癌治疗。
急切期待关于男性乳腺癌管理与治疗的证据。尽管受到任何回顾性病例系列的所有局限性的影响，但本研究结果首次表明艾日布林可用于男性乳腺癌治疗。
